marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-12-2024
Lixte Biotechnology Holdings Balance Sheet 2011-2024 | LIXT
Annual Balance Sheet Lixte Biotechnology Holdings
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | - | - | -5.07 M | -2.6 M | -4.27 M | -1.31 M | -200 K | -25.3 K | -44.4 K | -480 K | -1.66 M | -10 K |
Long Term Debt |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Total Current Liabilities |
314 K | 396 K | 303 K | 217 K | 238 K | 211 K | 373 K | 219 K | 286 K | 273 K | 322 K | 261 K | 351 K |
Total Liabilities |
- | - | - | 217 K | 238 K | 211 K | 373 K | 219 K | 286 K | 273 K | 320 K | 260 K | 350 K |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-48.5 M | -43.4 M | -37.1 M | - | -27.1 M | -24.6 M | -22.5 M | -20.7 M | -18.6 M | -15.7 M | -13 M | -11.6 M | -8 M |
Total Assets |
4.31 M | 5.56 M | 5.09 M | 5.23 M | 2.67 M | 4.34 M | 1.37 M | 433 K | 598 K | 539 K | 560 K | 1.75 M | 430 K |
Cash and Cash Equivalents |
4.2 M | 5.35 M | 4.82 M | 5.07 M | 2.6 M | 4.27 M | 1.31 M | 200 K | 25.3 K | 44.4 K | 475 K | 1.66 M | 14.3 K |
Book Value |
4.31 M | 5.56 M | 5.09 M | 5.01 M | 2.43 M | 4.13 M | 995 K | 215 K | 312 K | 266 K | 240 K | 1.49 M | 80 K |
Total Shareholders Equity |
3.99 M | 5.17 M | 4.79 M | 5.01 M | 2.43 M | 4.13 M | 995 K | 215 K | 312 K | 266 K | 236 K | 1.49 M | 79 K |
All numbers in USD currency
Quarterly Balance Sheet Lixte Biotechnology Holdings
| 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 219 K | - | - | - | - | - | - | - | 273 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | 15.8 K | - | - | - | 94.3 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-51.4 M | -50.5 M | -48.5 M | -47.4 M | -46.4 M | -44.8 M | -43.4 M | -41.8 M | -40.3 M | -38.7 M | -37.1 M | -35.1 M | -33.8 M | -32.1 M | -30.4 M | -30.4 M | -30.4 M | -30.4 M | -27.1 M | -27.1 M | -27.1 M | -27.1 M | -24.6 M | -24.6 M | -24.6 M | -24.6 M | -22.5 M | -22.5 M | -22.5 M | -22.5 M | -20.7 M | -20.7 M | -20.7 M | -20.7 M | -18.6 M | -18.6 M | -18.6 M | -18.6 M | -15.7 M | -15.7 M | -15.7 M | -15.7 M | -13 M | -13 M | -13 M | - | - | - | - | - | - | - | - | - |
Total Assets |
1.7 M | 2.67 M | 4.31 M | 5.23 M | 3.1 M | 4.33 M | 5.56 M | 6.82 M | 8.02 M | 4.12 M | 5.09 M | 6.33 M | 7.24 M | 7.89 M | 5.23 M | 5.23 M | 5.23 M | 5.23 M | 2.67 M | 2.67 M | 2.67 M | 2.67 M | 4.34 M | 4.34 M | 4.34 M | 4.34 M | 1.37 M | 1.37 M | 1.37 M | 1.37 M | 433 K | 433 K | 433 K | 433 K | 598 K | 598 K | 598 K | 598 K | 539 K | 539 K | 539 K | 539 K | 558 K | 558 K | 558 K | 558 K | 1.75 M | 1.75 M | 1.75 M | 1.75 M | 430 K | 430 K | 430 K | 430 K |
Cash and Cash Equivalents |
1.64 M | 2.6 M | 4.2 M | 5.11 M | 2.91 M | 4.09 M | 5.35 M | 6.56 M | 7.74 M | 3.78 M | 4.82 M | 5.96 M | 6.8 M | 7.74 M | 5.07 M | 5.07 M | 5.07 M | 5.07 M | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 4.27 M | 4.27 M | 4.27 M | 4.27 M | 1.31 M | 1.31 M | 1.31 M | 1.31 M | 200 K | 200 K | 200 K | 200 K | 25.3 K | 25.3 K | 25.3 K | 25.3 K | 44.4 K | 44.4 K | 44.4 K | 44.4 K | 475 K | 791 K | 475 K | 475 K | 1.66 M | 1.66 M | 1.66 M | 1.66 M | 14.3 K | 14.3 K | 14.3 K | 14.3 K |
Book Value |
- | - | - | - | - | - | 5.56 M | 6.82 M | 8.02 M | 4.12 M | 5.09 M | 6.33 M | 7.24 M | 7.89 M | 5.23 M | 5.23 M | 5.23 M | 5.23 M | 2.67 M | 2.67 M | 2.67 M | 2.67 M | 4.34 M | 4.34 M | 4.34 M | 4.34 M | 1.37 M | 1.37 M | 1.37 M | 1.37 M | 215 K | 433 K | 433 K | 433 K | 598 K | 598 K | 598 K | 598 K | 266 K | 539 K | 539 K | 539 K | 558 K | 558 K | 558 K | 558 K | 1.75 M | 1.75 M | 1.75 M | 1.75 M | 430 K | 430 K | 430 K | 430 K |
Total Shareholders Equity |
1.37 M | 2.25 M | 3.99 M | 4.92 M | 2.69 M | 4.08 M | 5.17 M | 6.41 M | 7.49 M | 3.47 M | 4.79 M | 6.07 M | 6.87 M | 7.65 M | 5.01 M | 5.01 M | 5.01 M | 5.01 M | 2.43 M | 2.43 M | 2.43 M | 2.43 M | 4.13 M | 4.13 M | 4.13 M | 4.13 M | 995 K | 995 K | 995 K | 995 K | 215 K | 215 K | 215 K | 215 K | 312 K | 312 K | 312 K | 312 K | 266 K | 266 K | 266 K | 266 K | 236 K | 236 K | 236 K | 236 K | 1.49 M | 1.49 M | 1.49 M | 1.49 M | 79 K | 79 K | 79 K | 79 K |
All numbers in USD currency